France

The French National Authority for Health (HAS) released new recommendations about add-on reimbursement of medical devices and medical aids from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in October 2024. Ten recommendations were published concerning the registration or modification of registration conditions/extension of indications for the medical devices in the List of Reimbursable Products and Services (LPPR). Opinions concern cardiovascular, peripheral vascular, neurovascular, and interventional radiology devices, as well as medical aids.

In October 2024, the Finnish Coordinating Center for Health Technology Assessment released a report aiming to summarize the results of the comparative analysis of Finnish Digi-HTA and French Early coverage of digital medical devices framework (PECAN) assessment criteria. The analysis focuses on the frameworks' general aspects and the cybersecurity requirements.

At the beginning of October 2024, the Ministry of Labor, Health, and Solidarity published the amounts awarded for the Health Economic Research Program (PRME) projects submitted in 2023 and selected for funding.

On October 9, 2024, the new version of the Nomenclature of Medical Biology Procedures (NABM 93) was released in France. Changes included the introduction of five new codes and wording modifications for several codes.

In October 2024, the updated version of the intra-DRG list was published in France. Three new devices were registered in the cardiovascular and neurovascular fields. Furthermore, one device was removed from the list, and the registration conditions for several devices were changed.

The French National Authority for Health (HAS) released new recommendations about add-on reimbursement of medical devices and medical aids from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in September 2024. Five recommendations were published concerning the registration or modification of registration conditions/extension of indications for the medical devices in the List of Reimbursable Products and Services (LPPR). Opinions concern endocrine and spine devices, as well as medical aids.

On September 6, 2024, the new version of the Nomenclature of Medical Biology Acts (NABM 92) was released in France. Various changes were implemented, including the introduction of one new code, modification of the coefficient B rating for a number of codes, and deletion of Article 4 "Minimum quotations" from the general provisions section of the NABM with 18 codes of this section.

On September 2, 2024, the French Ministry of Health released further details on the renewed support for innovation in medical biology and anatomopathology procedures via the Repository of Innovative Services outside the Nomenclature of biology and anatomopathology (RIHN) 2.0 including criteria for application.

The French National Authority for Health (HAS) released new recommendations about add-on reimbursement of medical devices from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in August 2024. Five recommendations were published concerning the registration of medical devices or modification of registration conditions/extension of indications for the medical devices in the List of Reimbursable Products and Services (LPPR). Opinions concern cardiovascular, peripheral vascular, neuromodulation, orthopedic, and spine devices.

On August 3, 2024, the Ministry of Labor, Health, and Solidarity published an Order in the Official Journal of the French Republic modifying the national neonatal screening program using laboratory examinations. Starting November 1, 2024, all newborns will be screened for sickle cell disease. Other modifications include organizational changes and modifications related to the timing of blood sample collection.

On August 2, 2024, the French National Authority for Health (HAS) published a report presenting the program for evaluating targeted high-throughput sequencing procedures. The program defined indications for which the technology will be evaluated with a view to its transitioning to regular reimbursement under the Statutory Health

On August 2, 2024, the HAS published positive opinions on the inclusion of targeted high-throughput sequencing of gene panels in the medical management of lung cancer, gastrointestinal stromal tumors, and chronic lymphocytic leukemia in the NABM Nomenclature. This is a consequence of the efforts to disburden the innovation funding budget and clean the List of IVD tests outside the Nomenclature (Liste des actes hors nomenclatures, AHN, i.e., the merged 2023 RIHN List and the Supplementary List funded outside Statutory Health Insurance via the research and innovation budget).